Stock
Ownership of a fraction of a corporation and the right to claim a share of the corporation's assets and profits equal to the amount of stock owned
IN listed securityListed on BOM
IN headquarteredHeadquartered in Bengaluru, Karnataka, India
Follow
Biocon Ltd
₹395.85
532523
Mar 19, 4:00:02 PM GMT+5:30 · INR · BOM · Disclaimer
Market news
Financial performance
| (INR) | Q3 2021 | Year/year change |
|---|---|---|
Revenue | 18.51B | 5.89% |
Net income | 1.69B | -16.86% |
| Diluted EPS | 1.40 | -18.13% |
| Net profit margin | 9.11% | -21.47% |
| Operating income | 2.13B | -28.98% |
| Net change in cash | - | - |
| Cash on hand | - | - |
| Cost of revenue | 5.60B | -3.01% |
About
Biocon Limited is an Indian biopharmaceutical company based in Bangalore, India founded by Kiran Mazumdar-Shaw. The company manufactures generic active pharmaceutical ingredients that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics, as well as, biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. In contract research services, Syngene International Limited, a publicly listed subsidiary of Biocon.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Biocon and Syngene together employ about 9200 personnel. Wikipedia
Founded
1978
Website
Employees
12,609
Key stats
Previous close
The last closing price
₹389.50
Day range
The difference between the high and low prices over the past day
₹385.50 - ₹398.00
Year range
The difference between the high and low prices over the past 52 weeks
₹235.80 - ₹487.70
Market cap
A valuation method that multiplies the price of a company's stock by the total number of outstanding shares.
469.95B INR
P/E ratio
The ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks
77.71
Dividend yield
The ratio of annual dividend to current share price that estimates the dividend return of a stock
0.13%
CDP Climate Change Score
A score provided by CDP (formerly the Carbon Disclosure Project) that rates a company on its climate transparency and performance
Primary exchange
Listed exchange for this security
NSE
About
Biocon Limited is an Indian biopharmaceutical company based in Bangalore, India founded by Kiran Mazumdar-Shaw. The company manufactures generic active pharmaceutical ingredients that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics, as well as, biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. In contract research services, Syngene International Limited, a publicly listed subsidiary of Biocon.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Biocon and Syngene together employ about 9200 personnel. Wikipedia
Founded
1978
Website
Employees
12,609
